Peloton Equity
Ted has over 25 years of experience in executive leadership positions within the clinical laboratory industry, including 15 years with Genova Diagnostics, a former FFC portfolio company. Under his leadership, Genova reached over $100 million in revenue, $30 million in EBITDA, and completed a successful sale to Levine Leichtman Capital Partners in 2013. Currently, Ted serves as CEO of Bako Diagnostics, a podiatry-focused clinical laboratory and products company.
Ted’s experience also includes stints at Eurofins Scientific, Quest Diagnostics, and Deloitte.
This person is not in any offices
Peloton Equity
1 followers
Peloton Equity is a newly-formed private equity firm that focuses exclusively on growth capital investing in the lower middle market of the healthcare industry. Peloton seeks to invest $15-30MM per company, and has the ability to invest more with co-investments. Peloton is the growth capital investment team spun-out of Ferrer Freeman & Company, which has over 40 years of combined investing experience. Peloton leverages its extensive healthcare network, value-building diligence and investment process, and portfolio management playbook to add value to its portfolio companies.